Company news
AIM ImmunoTech Inc. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
AIM ImmunoTech Announces Pricing of $8.0 Million Public Offering
July 29, 2025
AIM ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
July 28, 2025
AIM ImmunoTech Announces Recent Presentation on the Potential of Private-Public Partnerships for the Development of Oncology Therapies
July 2, 2025
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
June 20, 2025
AIM ImmunoTech Resumes Trading on NYSE American
June 17, 2025
AIM ImmunoTech Granted U.S. Patent Covering Methods of Manufacturing Therapeutic dsRNA, Including Ampligen®
June 12, 2025
AIM ImmunoTech Announces NYSE American Removal of Trading Suspension
June 12, 2025
Calls
The 5 newest of 10 calls. Every call is listed under its year.
- AIM Immunotech (NYSE American: AIM) Q2 2025 Earnings Call
Aug 20, 2025
Transcript - AIM Immunotech (NYSE American: AIM) Q4 2024 Earnings Call
Apr 1, 2025
Transcript - AIM Immunotech (NYSE American: AIM) Q3 2024 Earnings Call
Nov 15, 2024
Transcript - AIM Immunotech (NYSE American: AIM) Q2 2024 Earnings Call
Aug 16, 2024
Transcript - AIM Immunotech (NYSE American: AIM) Q1 2024 Earnings Call
May 16, 2024
Transcript
Decks
The 5 newest of 33 decks. Every deck is listed under its year.
- Technical Presentation (June 2026)
Technical · 10 slides · Jun 4, 2026
- Investor Presentation (February 2026)
Investor deck · 17 slides · Feb 5, 2026
- Investor Presentation (January 2026)
Investor deck · 29 slides · Jan 12, 2026
- Maxim Growth Conference Oct. 22-23, 2025
Conference · 20 slides · Oct 20, 2025
- Investor Presentation (August 2025)
Investor deck · 21 slides · August 2025